

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM676293

<b>SUBMISSION TYPE:</b>	RESUBMISSION		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>RESUBMIT DOCUMENT ID:</b>	900638885		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Wyeth LLC		08/06/2021	Limited Liability Company:
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Fera Pharmaceuticals, LLC		
<b>Street Address:</b>	134 Birch Hill Rd		
<b>City:</b>	Locust Valley		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	11560		
<b>Entity Type:</b>	Limited Liability Company: NEW YORK		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	0704866	PHOSPHOLINE IODIDE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	5162771449		
<b>Email:</b>	susan@ferapharma.com		
<b>Correspondent Name:</b>	Susan McDougal		
<b>Address Line 1:</b>	134 Birch Hill Rd		
<b>Address Line 4:</b>	Locust Valley, NEW YORK 11560		
<b>NAME OF SUBMITTER:</b>	Susan McDougal		
<b>SIGNATURE:</b>	/susan mcdougal/		
<b>DATE SIGNED:</b>	09/23/2021		
<b>Total Attachments: 4</b>			
source=Trademark Assignment Agreement Fully Executed 08-06-21#page1.tif			
source=Trademark Assignment Agreement Fully Executed 08-06-21#page2.tif			
source=Trademark Assignment Agreement Fully Executed 08-06-21#page3.tif			
source=Trademark Assignment Agreement Fully Executed 08-06-21#page4.tif			

## TRADEMARK ASSIGNMENT AGREEMENT

**THIS TRADEMARK ASSIGNMENT AGREEMENT** (this "**Assignment**") is made and entered into as of August 6, 2021 ("**Effective Date**") by and among Wyeth LLC, a Delaware limited liability company ("**Assignor**") and Fera Pharmaceuticals, LLC, a New York limited liability company ("**Assignee**").

**WHEREAS**, Assignor and Assignee are parties to that certain Asset Purchase Agreement, dated August 6, 2021 (the "**Purchase Agreement**"), pursuant to which Assignor has agreed to sell and Assignee has agreed to purchase the Acquired Assets (as such term is defined in the Purchase Agreement);

**WHEREAS**, Assignor is the owner of the entire right, title and interest in, to and under the trademark registration shown in Schedule A, in respect of all goods covered by the specifications thereof together with the associated goodwill (the "**Mark**");

**WHEREAS**, pursuant the Purchase Agreement, Assignor wishes to assign to Assignee, and Assignee wishes to acquire from Assignor, all right, title and interest to the Mark; and

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby sells, assigns, transfers and conveys to Assignee its entire right, title and interest in and to the Mark for Assignee's own use and enjoyment, and for the use and enjoyment of Assignee's successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made..


**AND, ASSIGNOR HEREBY** further agrees to execute, or to cause to have executed, any confirmatory assignment of the Mark that may be reasonably required in addition to the signing of this Assignment and reasonably requested by the Assignee, Assignee's successors, assigns or other legal representatives, in order to transfer to the Assignee the ownership of the Mark to effectuate the purposes of this Assignment, including, but not limited to, and distributing copies of the completed registrar transfer documents to the Assignee, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

Assignor hereby requests the United States Commissioner of Patents and Trademark to record Assignee as the assignee and owner of the Mark.

This Assignment may be executed in counterparts, each of which, when executed, shall be deemed an original, and all of which shall constitute one and the same agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party, it being understood that both parties need not sign the same counterpart.

**IN WITNESS WHEREOF**, Assignor and Assignee have caused this Assignment to be executed by their duly authorized representatives as of the Effective Date.

WYETH LLC

By:   
Name: Alison L.M. O'Neill  
Title: Vice President

FERA PHARMACEUTICALS, LLC

By: \_\_\_\_\_  
Name:  
Title:

IN WITNESS WHEREOF, Assignor and Assignee have caused this Assignment to be executed by their duly authorized representatives as of the Effective Date.

WYETH LLC

By: \_\_\_\_\_

Name:

Title:

FERA PHARMACEUTICALS, LLC

By: \_\_\_\_\_

Name: *FRANK J. DELLA FERA*

Title: *President*

SCHEDULE A

TRADEMARK

MarkName	Country	Goods covered by Registration	Status	Original Application Date	Application Number	Original Registration Date	Registration Number	Current Owner
PHOSPHOLINE IODIDE	United States	"Anticholinest erase preparations used in medicine" in International Class 5.	Registered	12/22/1959	72087782	09/27/1960	0704866	Wyeth LLC